This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Cramer: Outing the Perpetual Losers -- Part II

9. Merck (MRK) -- can these guys get a little bold, at least? Can they even attempt to bring out shareholder value? Did they get anything at all from that Schering-Plough merger? Was there any gain there? What the heck is going on at this company that it seems, with everything they try, they can no longer pull anything off? Also, why the heck did they hire the chief scientist of Amgen (AMGN), of all places, when they got rid of the previous underperformer? Amgen? That's about the only biotech that hasn't produced anything new in years, hence that company's acquisition of Onyx. How could Merck be so obtuse? I kept thinking they Merck have to do something to bring out value -- perhaps split up the company and sell is animal-health division, like Pfizer (PFE) did. One day they will. But Merck may actually be the only major pharmaceutical company that's doing nothing at all to create value. Maybe it's anti-value-creation? One day value will be unlocked, but it is discouraging, and the Action Alerts PLUS charitable trust finally threw in the towel on this one.

10. Oracle (ORCL) -- I'm so glad that CEO Larry Ellison is still paying himself $96 million for doing all of that heavy lifting that's gotten Oracle shareholders almost nothing in return. Here's a company that everyone still loves, even as it keeps missing quarter after quarter. It obviously has become so desperate about its lack of a cloud-computing business that it had to partner with Salesforce.com (CRM), the same company it's been dissing privately for years. At one point, Oracle, like Microsoft (MSFT) and like Intel (INTL), was a great company. Now it's just taking up space and paying people fortunes to work there. Oracle shareholders of the world unite and get on the payroll, so you can make fortunes like everyone else there. At least management has finally stopped saying that Sun Micro was a good acquisition.

That's about all the spleen-venting I can do in one day. I can't wait to savage the additional underperformers that Real Money contributors enter in Columnist Conversation.

At the time of publication, Cramer was long ___.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Our Tweets

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs